172 related articles for article (PubMed ID: 15455592)
1. Quality control of anti-tuberculosis fixed-dose combination formulations in the global market: an in vitro study.
Ashokraj Y; Agrawal S; Varma MV; Singh I; Gunjan K; Kaur KJ; Bhade SR; Kaul CL; Caudron JM; Pinel J; Panchagnula R
Int J Tuberc Lung Dis; 2004 Sep; 8(9):1081-8. PubMed ID: 15455592
[TBL] [Abstract][Full Text] [Related]
2. Quality control of anti-tuberculosis FDC formulations in the global market: part II-accelerated stability studies.
Ashokraj Y; Kohli G; Kaul CL; Panchagnula R
Int J Tuberc Lung Dis; 2005 Nov; 9(11):1266-72. PubMed ID: 16333936
[TBL] [Abstract][Full Text] [Related]
3. Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations.
Agrawal S; Panchagnula R
Int J Pharm; 2004 Dec; 287(1-2):97-112. PubMed ID: 15541917
[TBL] [Abstract][Full Text] [Related]
4. Dissolution testing of marketed rifampicin containing fixed dose combination formulations using a new discriminative media: a post marketing retrospective study.
Panchagnula R; Kumar Bajpai A; Agrawal S; Ashokraj Y
Pharmazie; 2006 Oct; 61(10):851-4. PubMed ID: 17069424
[TBL] [Abstract][Full Text] [Related]
5. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
Singh S; Mohan B
Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
[TBL] [Abstract][Full Text] [Related]
6. The physical and chemical stability of anti-tuberculosis fixed-dose combination products under accelerated climatic conditions.
Bhutani H; Mariappan TT; Singh S
Int J Tuberc Lung Dis; 2004 Sep; 8(9):1073-80. PubMed ID: 15455591
[TBL] [Abstract][Full Text] [Related]
7. Recent bioequivalence studies on fixed-dose combination anti-tuberculosis drug formulations available on the global market.
Pillai G; Fourie PB; Padayatchi N; Onyebujoh PC; McIlleron H; Smith PJ; Gabriels G
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S309-16; discussion S317-21. PubMed ID: 10593710
[TBL] [Abstract][Full Text] [Related]
8. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa.
McIlleron H; Wash P; Burger A; Folb P; Smith P
Int J Tuberc Lung Dis; 2002 Apr; 6(4):356-61. PubMed ID: 11936746
[TBL] [Abstract][Full Text] [Related]
9. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
10. Structures required, roles and responsibilities in maintaining laboratories for quality assurance of anti-tuberculosis fixed-dose combinations in accordance with the IUATLD/WHO statement.
Fourie PB; Spinaci S
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S368-70; discussion S381-7. PubMed ID: 10593720
[TBL] [Abstract][Full Text] [Related]
11. Proposed minimum registration requirements for fixed-dose combination anti-tuberculosis drugs.
Fourie PB
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S362-7; discussion S381-7. PubMed ID: 10593719
[TBL] [Abstract][Full Text] [Related]
12. The potential use of urinary excretion data for assessing the relative bioavailability of rifampicin in fixed dose combination anti-tuberculosis formulations.
Pillai G; Ellard GA; Smith PJ; Fourie PB
Int J Tuberc Lung Dis; 2001 Aug; 5(8):691-5. PubMed ID: 11495257
[TBL] [Abstract][Full Text] [Related]
13. Fixed-dose combination formulations for tuberculosis treatment.
Sbarbaro J; Blomberg B; Chaulet P
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S286-8. PubMed ID: 10593706
[No Abstract] [Full Text] [Related]
14. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms.
Agrawal S; Panchagnula R
Biopharm Drug Dispos; 2005 Nov; 26(8):321-34. PubMed ID: 16059874
[TBL] [Abstract][Full Text] [Related]
15. Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam.
Prabhu S; Ortega M; Ma C
Int J Pharm; 2005 Sep; 301(1-2):209-16. PubMed ID: 16046087
[TBL] [Abstract][Full Text] [Related]
16. Discrepancy among dissolution rates of commercial tablets as a function of dissolution method. part 6: rifampicin.
Ammar HO; Khalil RM
Pharmazie; 1996 Mar; 51(3):165-8. PubMed ID: 8900866
[TBL] [Abstract][Full Text] [Related]
17. In vitro evaluation of food effect on the bioavailability of rifampicin from antituberculosis fixed dose combination formulations.
Panchagnula R; Rungta S; Sancheti P; Agrawal S; Kaul CL
Farmaco; 2003 Nov; 58(11):1099-103. PubMed ID: 14572860
[TBL] [Abstract][Full Text] [Related]
18. Estimate of the global market for rifampicin-containing fixed-dose combination tablets.
Norval PY; Blomberg B; Kitler ME; Dye C; Spinaci S
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S292-300; discussion S317-21. PubMed ID: 10593708
[TBL] [Abstract][Full Text] [Related]
19. The evaluation of rifampicin bioavailabilities of fixed-dose combinations of anti-tuberculosis drugs: procedures for ensuring laboratory proficiency.
Ellard GA
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S322-4; discussion S351-2. PubMed ID: 10593711
[TBL] [Abstract][Full Text] [Related]
20. Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products.
Catalani E
Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S289-91; discussion S317-21. PubMed ID: 10593707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
